Patients with early-stage gastric cancer who receive Helicobacter pylori treatment may benefit from lower rates of metachronous gastric cancer and only mild adverse events.

Accredited CME from Imedex

In this Key Insights activity, Dr Scott Kopetz and conference chair David H Ilson discuss the key take-home messages from the meeting, with a particular focus on non-colorectal GI cancers.
This webcast contains the most clinically significant information on pancreatic, esophageal, gastric, anal, rectal, hepatocellular, and colorectal cancers, as well as the broader subjects of immune therapy, surgery, and multimodality therapy.

Conferences

On March 23rd and 24th, 2018, meeting co-chairs Axel Grothey, MD and David Ilson, MD, PhD will join 19 other expert faculty members to discuss colorectal and pancreatic cancers, rare tumors, immunotherapy and hepatobiliary cancers, among other hot topics at the 2018 Great Debates & Updates in GI Malignancies.
Journal of Clinical Pathways provides highlights from the annual Gastrointestinal Cancers Symposium in San Francisco, California (January 19-21, 2017).

At the second annual Oncology Nurse Advisor Navigation Summit (April 7-9, 2016; Orlando, FL), Teresa Labovich, MSN, RN, OCN, Penrose Cancer Center (Colorado Springs, CO), described a method by which gastrointestinal (GI) oncology nurse navigators (ONN) can play a role in improving institutional efficiency and patient outcomes. 

Read More

News

Patients with early-stage gastric cancer who receive Helicobacter pylori treatment may benefit from lower rates of metachronous gastric cancer and only mild adverse events.

Investigating genetic variations within a primary tumor, the differences between the primary tumor and a metastatic branch of that tumor, and additional diversity found in tumor DNA in the bloodstream could help guide and improve treatment choices in patients with gastroesophageal adenocarcinoma (GEA), according to a recent study.

Read More

Researchers compared the effects of proton beam therapy plus chemotherapy vs traditional radiation therapy plus chemotherapy in older patients undergoing surgery for esophageal cancer.

Read More

A recent study compared the effects of multiple adjuvant chemoradiotherapy regimens on overall survival (OS) in patients with gastric or gastroesophageal junction adenocarcinoma, published in the Journal of Clinical Oncology (online October 4, 2017; doi:10.1200/JCO.2017.74.2130).

Read More

Research in Review

A higher dose treatment for a type of metastatic gastric adenocarcinoma showed equivalent efficacy and safety, according to research published in the Journal of Clinical Oncology (published online June 2017; doi:10.1200/JCO.2016.71.6852).

-----

Related Content

Read More

A recent study showed that over 65% of cases of a certain tumor type were over-diagnosed or inaccurately risk-stratified, published in PLOS One (June 7, 2017;12[6]:e0179216).

-----

Related Content

Read More

Few patients with metastatic urothelial carcinoma of the bladder are surviving as long in the real-world as those in clinical trials, according to new research.

-----

Related Content

Read More

Administering capecitabine after surgery extends survival by a median of 17 months compared with surgery alone for patients with biliary tract cancer, according to research that will be presented at the 2017 ASCO Annual Meeting (June 2-6, 2017; Chicago, IL).

-----

Related Content

Read More

Resources

The National Comprehensive Cancer Network recently released treatment guideline updates for esophageal and esophagogastric junction cancers, involving a systemic therapy in the second-line setting.
Subscribe to Gastrointestinal Cancer